PhaseV Introduces ClinOps AI Platform to Improve Clinical Trial Operations
PhaseV has launched the ClinOps platform, an advanced AI-driven tool aimed at improving clinical trial operations with precision-guided site selection and real-time performance monitoring. This platform leverages causal machine learning and real-world patient-level data to help clinical teams make faster, more informed decisions throughout the trial lifecycle.
Unlike traditional site selection tools that rely on historical averages and static metrics, ClinOps models the factors influencing site performance and patient variability. It considers detailed patient characteristics such as age, BMI, ethnicity, comorbidities, genomics, and prior treatments. These insights align with the therapeutic asset's mechanism of action and eligibility criteria, enabling better site recommendations with higher recruitment success and improved patient diversity.
Precision-Guided Site Selection
ClinOps transforms site selection from a one-time feasibility task into an ongoing, interactive process. Users can explore global site options based on specific trial parameters, therapeutic context, and target populations. This adaptive approach reduces enrollment risks and avoids low-performing or congested sites, ultimately supporting more efficient and representative trials.
Real-Time Performance Monitoring
Once the trial begins, the platform provides continuous oversight through a centralized dashboard. It tracks enrollment trends, evaluates site performance, and detects risks early. Predictive models and intelligent alerts enable teams to respond quickly to any deviations or bottlenecks, helping keep trials on schedule and aligned with goals.
Support Across the Trial Lifecycle
- Pre-launch: Refines eligibility criteria and trial design based on modeled patient populations.
- Site selection: Identifies sites with the best fit using data-driven performance predictions.
- Post-activation: Monitors site activity in real time and adjusts plans proactively.
The ClinOps platform is already used by over 30 leading pharmaceutical, biotech sponsors, and CROs across more than 20 therapeutic areas. Its introduction coincides with the appointment of Melanie Ivarsson OBE, PhD, former Chief Development Officer at Moderna, to PhaseV's advisory board. Her experience in developing one of the first COVID-19 vaccines is expected to guide the platform's ongoing innovation and adoption.
PhaseV’s AI/ML solutions have demonstrated measurable benefits, including a 50% reduction in trial costs, a 40% decrease in enrollment size and trial duration, and a 30% increase in trial success probability. Their platform supports adaptive, Bayesian, and fixed trial designs while helping teams uncover treatment effect heterogeneity and optimize patient stratification.
For operations professionals seeking practical tools to improve clinical trial efficiency and outcomes, the ClinOps platform offers a data-rich, actionable solution that supports smarter decisions every step of the way.
Your membership also unlocks:
